Timing, distribution, and microbiology of infectious complications after necrotizing pancreatitis

Table 3 Drug sensitivity of Gram-negative bacteria in infected patients

	Pancreatic				Extrapancreatic
Antibiotic	P. aeruginosa	E. coli	A. baumannii	K. pneumoniae	P. aeruginosa	E. coli	A. baumannii	K. pneumoniae
MDR bacteria	9/34	9/34	16/22	15/30	8/32	4/20	17/22	11/16
ESBL +:	—	14/34	—	6/30	—	10/20	—	2/16
Penicillins
Ampicillin	0/34	8/34	0/22	1/30	0/32	4/20	1/22	0/16
Piperacillin	12/34	4/34	0/22	3/30	14/32	4/20	1/22	0/16
Enzymatic penicillins
Piperacillin/tazobactam	13/34	10/34	4/22	8/30	19/32	11/20	1/22	4/16
Cefoperazone/sulbactam	8/34	0/34	4/22	0/30	9/32	0/20	4/22	0/16
Ampicillin/sulbactam	0/34	4/34	0/22	4/30	0/32	6/20	4/22	0/16
quinolones
Levofloxacin	21/34	11/34	3/22	11/30	17/32	6/20	3/22	3/16
First- and second-generation cephalosporins
Cefoxitin	0/34	0/34	0/22	0/30	0/32	0/20	0/22	0/16
Cefuroxime	0/34	0/34	0/22	0/30	0/32	0/20	0/22	0/16
Third- and fourth-generation cephalosporins
Ceftazidime	14/34	13/34	3/22	7/30	16/32	11/20	3/22	2/16
Cefepime	17/34	12/34	3/22	10/30	15/32	11/20	3/22	3/16
Carbapenems
Imipenem	10/34	21/34	2/22	11/30	10/32	12/20	3/22	2/16
Meropenem	10/34	11/34	3/22	6/30	9/32	6/20	3/22	2/16
Sulfonamides
Compound trimethoprim	1/34	14/34	9/22	14/30	0/32	10/20	8/22	9/16
Tetracycline
Tigecycline	1/34	1/34	17/22	13/30	0/32	2/20	18/22	9/16
Minocycline	—	—	9/22	—	0/32	—	10/22	—

MDR: Multidrug-resistant; ESBL: Extended-spectrum β-lactamases; E. coli: Escherichia coli; P. aeruginosa: Pseudomonas aeruginosa; A. baumannii: Acinetobacter baumannii; K. pneumoniae: Klebsiella pneumoniae.